CY2012011I1 - Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο - Google Patents

Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο

Info

Publication number
CY2012011I1
CY2012011I1 CY2012011C CY2012011C CY2012011I1 CY 2012011 I1 CY2012011 I1 CY 2012011I1 CY 2012011 C CY2012011 C CY 2012011C CY 2012011 C CY2012011 C CY 2012011C CY 2012011 I1 CY2012011 I1 CY 2012011I1
Authority
CY
Cyprus
Prior art keywords
diuretic
pharmaceutical preparation
calcium channel
preparation containing
channel blocker
Prior art date
Application number
CY2012011C
Other languages
English (en)
Other versions
CY2012011I2 (el
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2012011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of CY2012011I2 publication Critical patent/CY2012011I2/el
Publication of CY2012011I1 publication Critical patent/CY2012011I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CY2012011C 2002-05-17 2012-05-14 Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο CY2012011I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38154602P 2002-05-17 2002-05-17
PCT/EP2003/005188 WO2003097098A1 (en) 2002-05-17 2003-05-16 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Publications (2)

Publication Number Publication Date
CY2012011I2 CY2012011I2 (el) 2015-11-04
CY2012011I1 true CY2012011I1 (el) 2015-11-04

Family

ID=29550141

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111101071T CY1112013T1 (el) 2002-05-17 2011-11-07 Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο
CY2012011C CY2012011I1 (el) 2002-05-17 2012-05-14 Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111101071T CY1112013T1 (el) 2002-05-17 2011-11-07 Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο

Country Status (24)

Country Link
US (3) US20050182042A1 (el)
EP (2) EP1507558B8 (el)
JP (2) JP5288678B2 (el)
KR (3) KR20130109244A (el)
CN (1) CN1655819A (el)
AT (1) ATE520417T1 (el)
AU (1) AU2003240669B2 (el)
BR (1) BR0310084A (el)
CA (1) CA2485081C (el)
CY (2) CY1112013T1 (el)
DK (1) DK1507558T3 (el)
EC (1) ECSP045428A (el)
ES (1) ES2369216T3 (el)
IL (1) IL164837A (el)
LU (1) LU92000I2 (el)
MX (1) MXPA04011383A (el)
NO (1) NO334382B1 (el)
NZ (1) NZ536555A (el)
PL (1) PL219032B1 (el)
PT (1) PT1507558E (el)
RU (1) RU2316318C2 (el)
SI (1) SI1507558T1 (el)
WO (1) WO2003097098A1 (el)
ZA (1) ZA200408442B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20050182042A1 (en) * 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
WO2004110354A2 (en) 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
TW200538154A (en) * 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds
PE20060075A1 (es) * 2004-03-17 2006-03-20 Novartis Ag Composiciones farmaceuticas de alisciren
WO2005089731A2 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
ES2336144T3 (es) * 2004-05-31 2010-04-08 Almirall, S.A. Combinaciones que comprenden agentes antimuscarinicos y corticosteroides.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
MX2007011697A (es) * 2005-03-22 2007-11-16 Novartis Ag Biomarcadores para eficacia de aliskiren como agente hipertensivo.
US20080261958A1 (en) * 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
BRPI0718546A2 (pt) * 2006-11-07 2013-11-19 Novartis Ag Formas cristalinas de hemifumarato de alisquireno
US20100130616A1 (en) * 2006-11-09 2010-05-27 Novartis Ag Salt of aliskiren with orotic acid
EP2094289B1 (en) * 2006-12-04 2013-03-13 Promedior, Inc. Combination of sap and enalapril for use in the treatment of fibrotic or fibroproliferative disorders
WO2008098992A1 (en) * 2007-02-16 2008-08-21 Novartis Ag Use of organic compounds
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
RU2363472C2 (ru) * 2007-05-22 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
DK2214666T3 (da) 2007-10-05 2014-01-27 Alzheimer S Inst Of America Inc Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
RU2373932C1 (ru) * 2008-05-20 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии
RU2372079C1 (ru) * 2008-05-20 2009-11-10 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
EP2405929B1 (en) * 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
WO2010104959A1 (en) * 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2443144B1 (en) * 2009-06-17 2015-08-19 Promedior, Inc. Sap variants and their use
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102552277A (zh) * 2011-12-02 2012-07-11 邬林祥 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
GB201317373D0 (en) 2013-10-01 2013-11-13 Univ Dundee Treatment and prevention of cancer
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
KR102414285B1 (ko) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5114925A (en) * 1991-01-22 1992-05-19 Merck & Co., Inc. Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040087484A1 (en) * 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
JP4194095B2 (ja) * 2001-09-11 2008-12-10 旭化成ファーマ株式会社 脳血管障害、心疾患の予防・治療用医薬組成物
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
US20050182042A1 (en) * 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic

Also Published As

Publication number Publication date
EP2316488A1 (en) 2011-05-04
CN1655819A (zh) 2005-08-17
AU2003240669A1 (en) 2003-12-02
PT1507558E (pt) 2011-11-23
US20120071470A1 (en) 2012-03-22
JP5288678B2 (ja) 2013-09-11
EP1507558A1 (en) 2005-02-23
CY2012011I2 (el) 2015-11-04
ATE520417T1 (de) 2011-09-15
US20080300238A1 (en) 2008-12-04
IL164837A0 (en) 2005-12-18
MXPA04011383A (es) 2005-02-14
CA2485081A1 (en) 2003-11-27
EP1507558B1 (en) 2011-08-17
KR20050008717A (ko) 2005-01-21
KR20100137026A (ko) 2010-12-29
JP2005526850A (ja) 2005-09-08
PL372203A1 (en) 2005-07-11
NO334382B1 (no) 2014-02-24
AU2003240669B2 (en) 2007-03-08
BR0310084A (pt) 2005-02-15
KR20130109244A (ko) 2013-10-07
ES2369216T3 (es) 2011-11-28
DK1507558T3 (da) 2011-12-05
SI1507558T1 (sl) 2011-12-30
NZ536555A (en) 2007-03-30
LU92000I2 (fr) 2012-07-16
RU2004137104A (ru) 2005-09-10
EP1507558B8 (en) 2012-02-15
US20050182042A1 (en) 2005-08-18
RU2316318C2 (ru) 2008-02-10
CY1112013T1 (el) 2015-11-04
CA2485081C (en) 2013-01-08
IL164837A (en) 2013-12-31
US8183295B2 (en) 2012-05-22
JP2010280708A (ja) 2010-12-16
NO20045459L (no) 2004-12-15
ZA200408442B (en) 2006-02-22
HK1074774A1 (en) 2005-11-25
PL219032B1 (pl) 2015-03-31
ECSP045428A (es) 2005-01-03
WO2003097098A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
CY2012011I1 (el) Φαρμακευτικο σκευασμα που περιεχει εναν αναστολεα ρενινης, εναν αποκλειστη διαυλων ασβεστιου και ενα διουρητικο
KR100984939B9 (ko) 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
AU2003224454A8 (en) Thiol compound, photopolymerization initiator composition and photosensitive composition
GB0218625D0 (en) Pharmaceutical compounds
IL166809A0 (en) Pharmaceutical nati-tnf-alpha antibody formulation
DK2266650T3 (da) Lægemiddeldispenser
GB0217225D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
DE60312993D1 (de) Umreifungsband
IL158083A0 (en) A PHARMACEUTICAL COMPOSITION CONTAINING AN Eg5 PROTEIN INHIBITOR
AU2003254844A1 (en) Substituted amino compounds and use thereof
GB0215775D0 (en) Pharmaceutical compounds
EP1673054A4 (en) TRANSITION STATE ANALOG HEMMER OF RICIN A CHAIN
DE50300879D1 (de) Verpackungs-Klebeband
EP1541139A4 (en) DRUG COMPOSITION WITH NF-KAPPA B HEMMER
AU2003240678A1 (en) Hydraulic tensioning device
DK1317256T3 (da) Farmaceutisk sammensætning havende en modificeret bærer
AU2003257102A1 (en) Pharmaceutical dosage form comprising a sulfite compound
IL164755A0 (en) Pharmaceutical composition containing a reversibleprotein pump inhibitor
DE10393274D2 (de) Palettiergerät
GB0204392D0 (en) Pharmaceutical compound
AU2003241991A1 (en) Drug composition containing calcium channel antagonist
DK200100146U3 (da) Bardun strammer
ITMI20022357A1 (it) Palettizzatore